FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: evidence from an Asian population-Reference-Cited by-同舟云学术

FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: evidence from an Asian population

Published:2021-06-22 Issue: Volume: Page:
ISSN:2095-0217
Container-title:Frontiers of Medicine
language:en
Short-container-title:Front. Med.

Author:

Wei Haoran,Zhao Mingming,Huang Man,Li Chenze,Gao Jianing,Yu Ting,Zhang Qi,Shen Xiaoqing,Ji Liang,Ni Li,Zhao Chunxia,Wang Zeneng,Dong Erdan,Zheng Lemin,Wang Dao Wen

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11684-021-0857-2.pdf

Reference32 articles.

1. Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, Daviglus ML, Lloyd-Jones DM. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol 2013; 61(14): 1510–1517

2. Sato N. Epidemiology of heart failure in Asia. Heart Fail Clin 2015; 11(4): 573–579

3. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472(7341): 57–63

4. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368(17): 1575–1584

5. Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, Wu Y, Hazen SL. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014; 64(18): 1908–1914

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis;Molecular Medicine;2024-08-23

2. Human Gut Microbiota in Cardiovascular Disease;Comprehensive Physiology;2024-06-27

3. Gut microbiota metabolites and risk of major adverse cardiovascular events and death: A systematic review and meta-analysis;Medicine;2024-05-31

4. Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases;Cardiovascular & Hematological Disorders-Drug Targets;2024-03

5. Therapeutic applications of gut microbes in cardiometabolic diseases: current state and perspectives;Applied Microbiology and Biotechnology;2024-01-20